Advancing the Development of Pediatric Devices
NCC-PDI brings together teams with excellence and expertise in delivering business, regulatory, legal, scientific, engineering, and clinical services for children.
Expert advice, support services, and fund management for pediatric device innovators.
A pipeline of high-potential pediatric devices for all pediatric subpopulations.
In September 2013, the Sheik Zayed Institute for Pediatric Surgical Innovation (SZI) at the Children’s National Health System and the University of Maryland A. James Clark School of Engineering received a U.S. Food and Drug Administration (FDA) P50 grant to form the National Capital Consortium for Pediatric Device Innovation (NCC-PDI).
In the News
While FY2017's approvals notably served all four pediatric age groups, the majority of pediatric devices approved over the last decade are not indicated for children under the age of 12. What's more, a large portion of the devices indicated for FDA's 'adolescents' category are only authorized for use in patients 18 or older.
The Houston, TX-based company is developing the Aortix system, a percutaneous blood pump initially targeted for treating patients with heart failure and worsening kidney function.
The investment will fund the company’s pilot study through the activities needed to support the submission of an FDA IDE application for its pivotal trial. To date, the firm said it has raised more than $59 million in funding.
Winning devices in pitch competition on track to advance pediatric surgical options in orthopedics and spine
WASHINGTON (Children's National) May 01, 2019
The National Capital Consortium for Pediatric Device Innovation (NCC-PDI) announced five winners of its “Make Your Medical Device Pitch for Kids!” competition who will each receive $50,000 in grant funding and access to the consortium’s first-of-its-kind “Pediatric Device Innovator Accelerator Program” led by MedTech Innovator. A panel of expert judges from business, healthcare, regulatory and legal sectors selected the winners based on the clinical significance and commercial feasibility of their medical devices for children. The competition focused solely on advancing care in pediatric orthopedics and spine, a sector that the FDA identified as an emerging underserved specialty which lacks innovation.